Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Roche Cervical Cancer Diagnostic Test Approved in China

publication date: Mar 9, 2016
Roche has been granted CFDA approval for its CINtec® PLUS Cytology test, which detects pre-cancerous cervical disease. In a China study, the CINtec Plus test was more effective than conventional screening tools such as the Pap smear for selecting the patients with the greatest risk of developing cervical cancer. Roche's Diagnostic Division is a major part of its China operation, and the CINtec Plus test joins Roche's other cervical cancer diagnostics -- the cobas® HPV Test for screening, CINtec® PLUS Cytology and CINtec® Histology for triage and diagnosis -- in women's health. More details....

Stock Symbol: (SIX: RO, ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital